Drugs / HS-10510
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07001787 Comparator | Jun 2025 → Feb 2026 overdue | hyperlipidemia | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10510 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07001787 ↗ |
| Route | Oral | “Subjects will receive HS-10510 orally as a single and multiple ascending dose.” NCT07001787 ↗ |